Week 2, September 2025: The Convergence of High-Volume Antibody Platforms

Recent advances in high-throughput technologies are reshaping the antibody discovery landscape, with platforms now capable of rapidly producing highly specific, naturally paired antibodies. As reviewed by Wang et al. (2025), antibody library display systems (phage, yeast, bacterial, and ribosome display) have matured through the integration of automation, next-generation sequencing, and microfluidics, enabling faster enrichment and broader repertoire recovery. In parallel, single-cell isolation methods such as droplet- and microwell-based microfluidics, now allow for the functional screening of millions of antibody-secreting cells with unprecedented precision. Emerging innovations suggest that the integration of high-throughput biophysical, cellular, and computational technologies are soon to come.

Recent Advances

oPool+ high-volume antibody display platform

Researchers from the University of Illinois have recently developed the oPool+ system which combines large-scale antibody production with parallelized binding assays, reducing the time for evaluating antibody–antigen interactions. In its first application, researchers profiled ~300 influenza hemagglutinin antibodies, uncovering shared binding features across diverse immune repertoires. Importantly, oPool+ reduces material costs by up to 90% and shortens experimental timelines from months to days. Beyond influenza, the platform is poised to rapidly identify therapeutic antibodies against emerging pathogens and to serve as a validation engine for AI-based antibody design models. 

HT-NaBS nanophotonics and bioprinting assay

Meanwhile, Stanford University researchers introduced HT-NaBS in a new preprint, a silicon nanophotonic and acoustic bioprinting-enabled platform capable of simultaneously screening antibody–antigen interactions with picomolar sensitivity. With independently functionalized nanosensors, the system quantitatively measures binding kinetics, affinity constants, and specificity. Demonstrated on antibodies against SARS-CoV-2, influenza, and therapeutic EGFR targets, HT-NaBS enables not only rapid affinity screening but also epitope binning, ensuring broad repertoire diversity. Their design marks a major step toward bridging computational protein design with empirical validation.

Rabbit mAb discovery via droplet microfluidics

Another recent paper by The Hong Kong University of Science and Technology researchers highlights a new workflow that integrates pan-B cell enrichment with droplet microfluidics to overcome the long-standing challenge of limited markers for rabbit B cells. By using magnetic negative selection and tailored antibody cocktails, they achieved a 7-fold enrichment in IgG secretion, enabling high-throughput screening of rabbit antibody repertoires. Droplet-based functional assays for both soluble and membrane antigens preserved natural VH–VL pairing and yielded antibodies with superior binding rates compared to previous reports. The approach accelerates rabbit mAb discovery, expanding their potential in diagnostics and precision therapeutics.

These exciting advancements in high-throughput antibody discovery are converging into integrated, automation-ready workflows that shorten timelines, reduce reagent consumption, and improve the probability of identifying high-affinity, epitope-diverse, and developable leads. For groups looking to accelerate programs or outsource their antibody discovery, Biointron is here to help! Learn more here: 

• VHH Antibody Discovery

• Single B Cell Screening

• Hybridoma Sequencing

• High-throughput Fully Human Antibody Discovery Platform